title: Progression to AIDS in relation to clinical factors and clotting product consumption. A 14-year follow-up of a cohort of 52 Dutch HIV-1-infected haemophilic patients.
abstract: OBJECTIVE
  In order to describe the progression of HIV disease in a cohort of Dutch HIV-1-infected patients with haemophilia and to study the influence of clinical and clotting factors, we performed a 15-year longitudinal clinical and laboratory study.
  
  
  METHODS
  The progression to AIDS in relation to type of haemophilia, antibodies against factor VIII, age, cytomegalovirus (CMV) infection, and type and total amount of clotting factor consumption was studied in 52 haemophilic patients infected with HIV-1 between 1981 and July 1985.
  
  
  RESULTS
  The progression to AIDS was faster in the group of patients with antibodies against factor VIII (inhibitors) and in the group of patients with haemophilia B than in the group of patients with haemophilia A without inhibitors.
  
  
  CONCLUSIONS
  We concluded that HIV-infected patients with haemophilia A with inhibitors and patients with haemophilia B show a significantly faster progression to AIDS than do HIV-infected patients with haemophilia A without inhibitors. These differences are independent of the total amount of clotting factor used and other known risk factors such as age at seroconversion and CMV infection and may be due to the type of clotting product used.
authors.affiliation: Van Creveld Clinic, University Hospital Utrecht, Utrecht, The Netherlands. G.Roosendaal@digd.azu.nl
authors.forename: G
authors.initials: G
authors.lastname: Roosendaal
authors.forename: Y
authors.initials: Y
authors.lastname: van der Schouw
authors.forename: E
authors.initials: E
authors.lastname: Mauser-Bunschoten
authors.forename: J
authors.initials: J
authors.lastname: Borleffs
authors.forename: H
authors.initials: H
authors.lastname: van den Berg
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000276:immunology; D018450:Disease Progression; D005500:Follow-Up Studies; D006679:HIV Seropositivity; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy*; D002836:Hemophilia B / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008875:Middle Aged
chemical_list: D001779:Blood Coagulation Factors